Home
Resources
Publications
Prospective Randomized Comparison of Mezlocillin Therapy Alone With Combined Ampicillin and Gentamicin Therapy for Patients With Cholangitis

Prospective Randomized Comparison of Mezlocillin Therapy Alone With Combined Ampicillin and Gentamicin Therapy for Patients With Cholangitis

W B Gerecht, N K Henry, W W Hoffman, S M Muller, N F LaRusso, J E Rosenblatt, W R Wilson

Arch Intern Med. 1989 Jun;149(6):1279-84.

PMID: 2658897

Abstract:

Forty-six patients with cholangitis were randomized to receive therapy with mezlocillin sodium (24 patients) or a combination of ampicillin sodium--gentamicin sulfate (22 patients). The biliary concentration of mezlocillin was 112 times higher than that of ampicillin and 778 times higher than that of gentamicin. The ratio of the concentration in serum or bile over the minimum inhibitory concentration against aerobic gram-negative bacilli (therapeutic index) was higher for mezlocillin than for either ampicillin or gentamicin. Twenty (83%) of 24 patients were cured following mezlocillin therapy compared with 9 (41%) of 22 patients after ampicillin-gentamicin therapy. The 3 patients with superinfection were in the ampicillin-gentamicin arm of the study. Fewer toxic or adverse effects occurred in association with mezlocillin treatment than with ampicillin-gentamicin treatment. Mezlocillin therapy was more effective, less toxic, and less expensive than treatment with ampicillin and gentamicin for patients with cholangitis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP42057227	Mezlocillin sodium		42057-22-7	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: